Thermo Fisher Scientific Inc. (NYSE:TMO - Get Free Report) CEO Marc N. Casper sold 5,850 shares of the company's stock in a transaction dated Friday, November 1st. The shares were sold at an average price of $557.89, for a total transaction of $3,263,656.50. Following the transaction, the chief executive officer now directly owns 121,192 shares of the company's stock, valued at approximately $67,611,804.88. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
Thermo Fisher Scientific Stock Performance
Thermo Fisher Scientific stock opened at $555.47 on Tuesday. The stock has a market cap of $212.19 billion, a P/E ratio of 34.83, a price-to-earnings-growth ratio of 3.61 and a beta of 0.79. The company has a current ratio of 1.63, a quick ratio of 1.26 and a debt-to-equity ratio of 0.64. The stock has a 50 day moving average of $598.39 and a 200-day moving average of $583.86. Thermo Fisher Scientific Inc. has a 52 week low of $437.26 and a 52 week high of $627.88.
Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its quarterly earnings results on Wednesday, October 23rd. The medical research company reported $5.28 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.25 by $0.03. The business had revenue of $10.60 billion for the quarter, compared to analyst estimates of $10.63 billion. Thermo Fisher Scientific had a return on equity of 17.49% and a net margin of 14.48%. The business's revenue was up .2% compared to the same quarter last year. During the same period in the prior year, the company posted $5.69 EPS. On average, analysts expect that Thermo Fisher Scientific Inc. will post 21.68 EPS for the current fiscal year.
Institutional Investors Weigh In On Thermo Fisher Scientific
I was wrong. Dead wrong.
From Porter & Company | Ad
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was.
Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.
Here’s the full story for you.
Several institutional investors and hedge funds have recently made changes to their positions in the company. Bond & Devick Financial Network Inc. acquired a new stake in shares of Thermo Fisher Scientific during the 3rd quarter valued at approximately $202,000. Catalytic Wealth RIA LLC raised its position in shares of Thermo Fisher Scientific by 38.8% during the 3rd quarter. Catalytic Wealth RIA LLC now owns 5,890 shares of the medical research company's stock valued at $3,643,000 after acquiring an additional 1,648 shares in the last quarter. Chartwell Investment Partners LLC increased its position in Thermo Fisher Scientific by 45.8% in the third quarter. Chartwell Investment Partners LLC now owns 17,496 shares of the medical research company's stock worth $10,823,000 after buying an additional 5,496 shares during the period. Peregrine Asset Advisers Inc. increased its position in Thermo Fisher Scientific by 830.5% in the third quarter. Peregrine Asset Advisers Inc. now owns 5,313 shares of the medical research company's stock worth $3,286,000 after buying an additional 4,742 shares during the period. Finally, Kennebec Savings Bank acquired a new stake in Thermo Fisher Scientific in the third quarter worth $761,000. 89.23% of the stock is owned by institutional investors and hedge funds.
Analyst Ratings Changes
TMO has been the subject of a number of research analyst reports. Raymond James upped their price objective on shares of Thermo Fisher Scientific from $650.00 to $660.00 and gave the company an "outperform" rating in a research note on Thursday, July 25th. Stephens initiated coverage on shares of Thermo Fisher Scientific in a research note on Tuesday, October 1st. They set an "overweight" rating and a $680.00 price objective for the company. JPMorgan Chase & Co. upped their price objective on shares of Thermo Fisher Scientific from $650.00 to $670.00 and gave the company an "overweight" rating in a research note on Friday, September 20th. Bernstein Bank boosted their target price on Thermo Fisher Scientific from $565.00 to $625.00 and gave the stock a "market perform" rating in a report on Tuesday, October 22nd. Finally, Robert W. Baird decreased their target price on Thermo Fisher Scientific from $632.00 to $622.00 and set an "outperform" rating for the company in a report on Thursday, October 24th. Four investment analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $649.33.
Check Out Our Latest Report on TMO
About Thermo Fisher Scientific
(
Get Free Report)
Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
